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ABSTRACT
Botulinum neurotoxin type-A (BoNT/A) formulations are widely used in clinical practice. Although they share a common mecha-
nism of action resulting in presynaptic block in acetylocholine release, their structure and pharmacological properties demonstra-
te some similarities and many differences. Bioequivalence has been discussed since the onset of the clinical use of BoNT/A. In this 
review, we provide an update on the studies and compare the molecular structure, mechanisms of action, diffusion and spread, 
as well as immunogenicity and dose equivalence of onabotulinumtoxinA, abobotulinumtoxinA and incobotulinumtoxinA. 
Key words: botulinum toxin A formulation, pharmacological similarities and differencies, abobotulinumtoxinA, onabotulinum-
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Introduction
Botulinum toxins are ‘natural products’ of living bacteria 
of the genus Clostridium. Particular therapeutics of botulinum 
toxin, although based on the same serotype A formulations 
(BoNT/A), have distinct properties. The main three BoNT/A 
products commercially available worldwide today are derived 
from Clostridium botulinum Hall strain:  onabotulinum-
toxinA  (ONA-BoNT/A) marketed as Botox/Vistabel by 
Allergan Inc. (Irvine, CA, USA); abobotulinumtoxinA (ABO-
BoNT/A) marketed as Dysport/Azzalure by Ipsen/Galderma 
(Paris, France); and incobotulinumtoxinA (INCO-BoNT/A) 
marketed as Xeomin/Bocouture by MerzPharmaceuticalGmbh 
(Frankfurt, Germany).
New BoNT/A formulations have recently been introduced 
to the market: prabotulinumtoxinA-xvfs (PRA-BoNT/A) mar-
keted as Jeuveau/Nabota/Nuceiva by Evolus/Daewoong and 
daxibotulinum toxin A (DAXI-BoNT/A) (formerly RT002) by 
Revance. Additionally, letibotulinum toxinA (Croma/Hugel 
with Botulax) is in Phase III trials although results have not 
been published yet.
Botulinum neurotoxin type-A preparations use in clini-
cal practice is based on presynaptic chemical denervation of 
cholinergic synapses due to the cleavage of specific synaptic 
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proteins. This results in a decrease of acetylocholine release. 
Despite the common mechanism, these preparations are 
distinct medications, with many differences in terms of their 
structure, potency and immunogenicity. These differences may 
result in differing clinical efficacy and safety as well as phar-
macoeconomic profiles, and have been discussed in medical 
literature over many years.
The aim of this paper was to show pharmacological 
similarities among, and differences between, the three most 
widely used BoNT/A preparations: ONA-, ABO-, and IN-
CO-BoNT/A.
Structure
ONA-BoNT/A and ABO-BoNT/A are purified neurotox-
in complexes including the BoNT/A1 and BoNT/A2 toxin 
molecules, respectively, and neurotoxin accessory proteins: 
NAPs - three haemagglutinin (HA) proteins and one non-toxic 
non-HA protein. It has been suggested that non-toxic HA not 
only stabilises the biological activity of the product in vivo, 
but also enables HA-botulinum toxin complex to adhere to 
muscle tissue [1]. INCO-BoNT/A contains only purified 
BoNT/A1 [2–4]. Results from a few studies have shown that 
~150 kDa BoNT/A protein is mostly linked with NAPs [5, 
6] at physiological pH levels, but other studies have suggested 
that prior to or shortly after injection the NAPs dissociate 
from botulinum toxin [7, 8]. Another study concluded that 
ONA-BoNT/A and ABO-BoNT do not contain neurotoxins 
in complexed form [8]. All commercial products contain an 
excipient, known as human serum albumin (HSA), which 
improves toxin stability and diminishes toxin loss during 
lyophilisation, prevents protein aggregation and surface ad-
sorption, as well as extends shelf life [4]. 
ONA-BoNT/A is vacuum dried, while ABO-BoNT/A 
and INCO-BoNT/A are freeze dried. All formulations before 
clinical use are reconstituted with sterile normal saline buffer, 
yielding a solution that is slightly acidic [9, 10]. The recon-
stitution processes of ONA-BoNT/A results in a complete 
dissociation of 900 kDa complexes and the release of more 
than 85% of neurotoxins in free form [8].
A comparison of selected characteristics of BoNT/A 
preparations is set out in Table 1.
Mechanism of action
The activity of the botulinum toxin known as ‘chemical 
denervation’ refers to the decrease of the pre-synaptic release 
of acetylcholine, and temporary muscle paresis or inhibition 
Table 1. Comparison of selected characteristics of botulinum toxin type-A preparations based on Frevert 2015 [3], Kutschenko et al. 2016 [42]*, Pirazzini et al. 
2017 [11],  Ferrari et al. 2018 [80], and Field et al. 2018 [81]**
Botox/Vistabel Dysport/Azzalure Xeomin/Bocouture






C. botulinum strain Hall A-hyper Hall A Hall A (ATCC 3502)
Toxin type A1 A1 A1
Molecular Weight (MW) 900 kDa complex Not reported 150 kDa
Purification method Crystallisation Chromatography Chromatography
Pharmaceutical form for recon-
stitution
Vacuum-dried powder Freeze-dried powder Freeze-dried powder
Shelf life 2–8°C/36 months 2–8°C/24 months Room temperature/36 months
Storage after reconstitution Up to 24 h at 2–8°C Up to 8 h at 2–8°C Up to 24 h at 2–8°C
pH (reconstituted) 7.4 7.4 7.4
Excipients in vial 100 U: human serum albumin  
0.5 mg, NaCl 0.9 mg 
500 U: human serum albumin  
0.125 mg, lactose 2.5 mg
100 U: human serum albumin  
1 mg, sucrose 4.7 mg
Unit/vial 100 U or 200 U Botox/50 U Vistabel 300 U or 500 U Dysport/ 
125 U Azzalure
100 U or 200 U Xeomin/ 
/50 U Bocouture
Protein load/vial 5 ng/100 U 4.35 ng/500 U 0.44 ng/100 U




~0.65 ng/100 U 
~0.54 ng/100 U**
~0.44 ng/100 U 
~0.40 ng/100 U**
Specific potency of 150 kD BoNTA 
neurotoxin
137 units/ng 154 units/ng 227 units/ng
Wheel-running performance of 
mice study activity in relation to 
ONA- BoNTA*
1 2.0 1.3–2.0
Unit testing Cell-based potency assay specific 
to Allergan BoNT/A product
LD50 assay specific to Ipsen BoNT/A 
product
LD50 assay specific to Merz BoNT/A 
product
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of glandular secretion. Additionally, BoNT/A inhibits the 
release of other neurotransmitters and influences inflam-
matory cells. This is probably the basis of its antinociceptive 
activity [11].
The mechanism of action of botulinum toxin A includes: 
1. binding to nerve terminals;  2. internalisation within an 
endocytic compartment; 3. translocation into the cytosol; 
4. the cleavage of SNARE complex by L chain; and 5. reduction 
of acetylcholine release from the pre-synaptic terminal.
1. In detail, according to 1., the C-terminal heavy chain (H) 
contains a translocation domain (HN) and a receptor 
binding domain (HC). The HC includes an N-terminal 
subdomain (HCN) of unspecified function and a C-ter-
minal subdomain (HCC) that selectively bonds to dual 
neuron-specific receptors - ganglioside GT1b, and the pro-
tein receptor SV2C on the presynaptic plasma membrane 
in particular neurons [12, 13]. BoNT serotype A1 and 
A2 binds to the glycosylated SV2C receptor synaptic 
vesicle glycoprotein 2C (SV2C) [13], which allows for 
rapid penetration of toxins, at similar rates, via the same 
synaptic vesicles. HCA2 has higher affinity for receptor 
and neurons than HCA1 [14].  Glycosylation Asn559 in 
SV2C is critical for binding of BoNT/A to presynaptic 
plasma membrane.  Glycosylation patterns in this site vary 
among adult individuals [15].  Pirazzini et al. have sug-
gested that this feature may be responsible for a different 
onset and duration of induced neuroparalysis in humans 
following administration of the same dose of BoNT/A1; 
probably, different amounts of bound toxin are likely to 
match different numbers of L chains entering the cytosol 
in nerve terminal [11]. 
2. The toxin enters the synaptic vesicles of motor axon 
terminals by endocytosis. Internalisation of BoNT/A is 
mediated by receptor of a polysialoganglioside (PSG), 
the glycosylated luminal domain of a synaptic vesicle 
protein and unique N-glycans attached to synaptic vesicle 
(SV) glycoproteins [16], as well as to E-cadherin [17–19], 
fibroblast growth factor and vanilloid receptors [20, 21]. 
The increased endocytosis rate of BoNT/A and a frequent 
exposure of the SV lumen was observed during stimulation 
of nerves. It has been demonstrated [18] that nontoxic HA 
protein (present in ONA- and ABO-BoNT/A) sequesters 
E-cadherin in the monomeric state, disrupts the intercellu-
lar epithelial barrier, and facilitates paracellular absorption 
of BoNT/A [20, 22].
3. The L chain (L) of toxin is translocated across the vesicle 
membrane into the cytosol. Acidification of the synaptic 
vesicle lumen triggers HN to form a channel to L trans-
location. Next, the L chain is released from H chain by 
reduction of the interchain disulfide bond.
4. Next, L chain cleaving the soluble N-ethylmaleimide-sen-
sitive factor attachment protein receptors (SNAREs), 
particularly synaptosomal associated protein of 25 kDa, 
SNAP-25.
5. Finally, SNAP-25 prevents the docking and exocytosis of 
acetylcholine from pre-synaptic vesicles at neurosecretory and 
neuromuscular junctions. Detailed mechanism of nerve pare-
sis by BoNT/A is described in a review by Pirazzini et al. [11]. 
The study by Grando and Zachary [23] presented the 
non-neuronal and non-muscular mechanisms and effects 
of BoNT/A in many normal and cancer cell lines. Differen-
tially altered genes expression by BoNT/A involved in signal 
transduction, immunity and defence, protein metabolism 
and modification, neuronal activities, intracellular protein 
trafficking and muscle contraction [24] show the huge range 
of mechanisms and possible effects of botulinum toxin. For 
example, ONA-BoNT/A injection markedly reduced, by 53%, 
urothelial ATP release in patients with spinal cord injury [25], 
increased nitric oxide (NO) release from the urothelium in 
the bladder detrusor [26], decreased expression of purinergic 
receptors (P2X3) in the bladder mucosa [27], inhibited the 
evoked release of CGRP from afferent nerve terminals in the 
bladder reducing pain [28], reduced bladder inflammation by 
decreasing urothelial apoptosis and the expression of vascular 
endothelial growth factor in the bladders of patients with 
interstitial cystitis (IC)/bladder pain syndrome (BPS) [29]. 
Recent studies have revealed that BoNT/A has antinocicep-
tive peripheral effects by blocking synaptic transmission of 
glutamate, dopamine, ATP and gamma-aminobutyric acid 
regulation and serotonin [30].  
The results of analysis of over 40,000 BoNT/A treatment 
reports indicate that patients who received BoNT/A in a broad 
range of injection sites had a significantly lower number of 
depression reports compared to patients undergoing different 
treatments for the same conditions [31]. Such results have 
allowed for the introduction of ONA-BoNT/A in Phase III 
studies designed so as to obtain FDA indication for major 
depression [32, 33].
The main mechanism of the ability of BoNT/A to weaken 
hyperactive secretory cells and relax tense muscles is the 
same for currently registered preparations, while the detailed 
additional effects mentioned above are described for ONA- 
-BoNT/A only.
Diffusion and spread out 
Distant effects of BoNT/A formulations may be the result 
of haematogenous spread defined as migration in local and 
regional muscles [34, 35], or as distant migration in areas 
non-contiguous with the injection [36–39]. Diffusion is char-
acterised as microscopic movement of a soluble molecule’s 
dispersion by passive transport to local and distant tissues [40] 
away from the intended area to nearby anatomical structures. 
The local spread of all BoNT/A formulations after injection 
depends on dilution, needle size, dose and volume, as well 
as injection technique [41]. Kutschenko et al. [42] suggested 
that the volume of injection is one of the major factors influ-
encing the degree of muscle paralysis. The volume-dependent 
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reduction of paresis in a wheel-running test was observed in 
mice injected with INCO-BoNT/A. Kutschenko et al. sug-
gested that larger volumes induce more intense paresis [42]. 
Pirazzini et al. suggested that the amount of toxin needed for 
a certain application should be diluted according to the size 
of the muscle/area [11]. Based on this data, it may be con-
sidered that the diffusion of BoNT/A from the injection site 
is increased by its gradual dilution in increasing volumes of 
extracellular fluids thus diminished binding to the presynap-
tic membrane. Additionally, different degrees of paresis after 
ONA-BoNT/A, ABO-BoNT/A and INCO-BoNT/A were 
presented after injecting identical volumes (10 μL) containing 
the same number of mouse units of BoNT/A into both hind 
leg muscles. Based on this experiment, the conversion ratio 
of INCO-BoNT/A and ONA-BoNT/A was estimated as being 
between 1:0.75 and 1:0.5. ONA-BoNT/A has shown a two-fold 
greater potency than ABO- BoNT/A [42]. 
Aoki et al. [36] proposed that protein complex size and 
pharmacological properties influence the diffusion of BoNT/A. 
That study showed that high-molecular-weight toxin com-
plex of ONA-BoNT/A limits tissue distribution compared to 
ABO-BoNT/A [36].  More recent studies in which the size of 
anhidrotic halos was measured have shown different results. 
A comparison of ONA-BoNT/A and ABO-BoNT/A (using 
dose ratios of 1:2.5, 1:3, and 1:4, and identical injection vo - 
lumes) presented a larger area of anhidrosis after ABO- 
-BoNT/A [43]. Kerscher et al. obtained different mean max-
imal areas of the forehead anhidrosis of patients at 6 weeks 
after injection of BoNT/A formulations: comparable spread 
to ONA-BoNT/A and INCO-BoNT/A, and significantly 
greater to ABO-BoNT/A [44]. In another study, no signif-
icant differences between the mean size of halos produced 
by ONA-BoNT/A and ABO-BoNT/A were observed [45]. 
Similarly, no differences in diffusion of ONA-BoNT/A and 
INCO-BoNT/A injected to forehead at the same dose and 
using the same technique were demonstrated after 6 weeks and 
6 months [46]. In other study, similar, limited to a distance 
of 30–45 mm [41], diffusion from the site of injection has 
been well documented by N-CAM staining and characterised 
ONA-BoNT/A, INCO-BoNT/A and ABO-BoNT/A when they 
were used in a ratio of 1: 1: 4 and in the same toxin injection 
volume (25 µL) [47].
Results from the study by Brodsky et al. showed that the 
presence of complexing proteins in ONA-BoNT/A and ABO-
-BoNT/A does not reduce migration of the neurotoxin [48]. 
The diffusion for all formulations of BoNT/A is similar in 
the majority of studies, but the dose and volume of injection 
may be the most important factors in differentiating diffusion 
efficiency.
The retrograde axonal transport of BoNT/A to spinal 
motor neurons, followed by anterograde transport to the other 
motor units, has also been suggested [49]. Caleo et al. [50] 
showed that BoNT/A physically leaves the motoneurons to 
enter second-order neurons. After injection of ONA- BoNT/A 
into the nasolabial musculature of rats and mice, catalytically 
active ONA-BoNT/A was transported to the facial nucleus. 
The authors suggested that these findings highlight cell-spe-
cific, direct central actions of BoNT/A, which are important 
to fully understand its mechanisms of action and therapeutic 
effectiveness in movement disorders and pain treatment. 
A few studies have shown that BoNT/A, injected intra-
muscularly, is transported both anterogradely along sensory 
axons and retrogradely by central neurons and motoneurons 
axons to the motoneuron soma in the spinal cord [51–54]. Au-
tophagosomes undergo dynein-dependent retrograde axonal 
transport to the neuronal soma [55]. Moreover, Antonucci et 
al. observed SNAP-25 cleavage in the contralateral hemisphere 
after unilateral BoNT/A delivery to the hippocampus [51]. 
Harper et al. and Restani et al. showed that BoNT/A-HC is 
internalised in synaptic vesicles and undergoes retrograde 
trafficking [56, 57]. The retrograde axonal transport and 
transcytosis to second-order nociceptive neurons explains 
mechanisms of action of ONA-BoNT/A in migraine [58]. 
ONA-BoNT/A is the only one approved for the treatment of 
chronic migraine. Selected papers have presented retrograde 
transport for ONA-BoNT/A only.
According to the Simpson et al. study, botulinum toxin 
accesses the perineuronal fluid compartment and does not 
cross the blood-brain barrier [59]. These authors suggested 
that BoNT/A is a large molecule and it is not able to cross the 
blood–brain barrier.  
Immunogenicity
Antibody formation against the accessory proteins was 
observed in patients after injection of BoNT/A formulation 
with associated proteins, but they did not interfere with the 
biological activity of the toxin (‘non-neutralising’) [60]. 
Results from a preclinical study suggest that the NAPs may 
physically secure neurotoxin against the immune system and 
finally against the formation of toxin-neutralising antibodies 
interfering with clinical response [61]. However, antibodies 
formed against the heavy chain may or may not prevent its 
biological activity. The immunological response of humans to 
BoNT/A is very low, ranging from 0% to 3%: 0% was reported 
for ONA-BoNT/A [62, 63] and for ABO-BoNT/A used in 
glabellar lines [63], 1.2% for ONA-BoNT/A [62, 63], less than 
3%  for ABO-BoNT/A in cervical dystonia [63], and 1.1% for 
INCO-BoNT/A in upper limb spasticity. Each patient injected 
with INCO-BoNT/A was previously treated with a botulinum 
toxin A product which contained complexing proteins [7, 64]. 
A comprehensive meta-analysis of 61 studies by Fabbri et al. 
[65] analysed the frequency of antibodies among 8,525 pa-
tients receiving all registered types of BoNT/A across several 
clinical indications. Generally, the prevalence of antibodies 
among clinically responding patients was lower (3.5%) than 
in secondary nonresponse patients (53.5%). The frequencies 
of antibody formation independent of clinical responsiveness 
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to BoNT/A formulations across all analysed clinical indications 
were 1.5% for ONA- BoNT/A, 1.7% for ABO-BoNT/A, and 0.5% 
for INCO-BoNT/A. The results of this analysis indicate the lowest 
frequency of antibody formation after INCO-BoNT/A. The pro-
spective, single-arm, dose-titration TOWER study showed that no 
patient with spasticity with a cerebral cause developed secondary 
nonresponse due to neutralising antibodies after administration 
of INCO-BoNT/A in a range of doses between 400 j and 800 j [66]. 
Based on the results of the aforementioned studies, the 
presence of complexing proteins in BoNT/A formulations may 
increase the risk of the formation of neutralising antibodies. 
The immunogenicity of the BoNT/A formulations depends 
on some factors that differ in the manufacturing process, 
mainly the source of toxin and the antigenic protein load 
and the presence of inactive or denatured toxin acting as 
a toxoid. Treatment-related factors such as the toxin dose, 
frequency of injections, as well as prior exposure via other 
routes (intradermal or distant to the target muscle), different 
formulations (e.g. first application of ONA-BoNT/A or ABO- 
-BoNT/A and second of INCO-BoNT/A) and site of anatomi-
cal region (especially near lymph nodes) seem to play a role in 
the immunogenic response. Based on this knowledge, clinical 
practice suggests the use of the lowest effective doses and to 
maintain 12 weeks of minimal interval treatment [67]. On the 
other hand, shorter, less than half as long, intervals of injection 
of INCO-BoNT/A have been described as well tolerated and 
free of antibodies [68].  
Doses 
A dose equivalence of BoNT/A formulations is still being 
discussed. The potency of BoNT/A preparations is expressed 
as Units (U) and 1U corresponds to one LD50 in mouse bioas-
say [69, 70]. Different diluents for LD50 testing have used by 
manufacturers: Allergan uses saline [71]; Ipsen uses gelatin 
phosphate buffer [72]; human serum albumin as a stabiliser 
was added by Merz to undisclosed diluent [73]. However, it 
has been suggested that stabilisers can enhance the activity of 
BoNT/A products at low concentrations in preclinical tests [74]. 
It is suggested that the diluent buffer significantly influences 
biological activity of BoNT/A products. Nonparallel dose-
response curves of ONA-BoNT/A and ABO-BoNT/A with 
different relative potencies can explain a dose conversion ratio 
between Botox and Dysport of 1:2.5–3 [74, 76] or 1:2 [43]. 
There are no internationally accepted standardised tests for 
BoNT/A product comparisons. For this reason, different assay 
methods with different proprietary product-specific reference 
standards for testing potency units are used. The clinical effect 
of one unit is not interchangeable between formulations due to 
differences in the bioassay methodologies used by producers 
[77]. The clinical literature has reported an equivalent potency 
between ONA-BoNT/A and INCO-BoNT/A [3], but this was 
not the case in an animal (mouse) study [42]. The potency of 
INCO-BoNT/A and ONA-BoNT/A in inducing hind limb 
paresis in the wheel-running performance test in mice showed 
a conversion rate of between 1: 0.75 and 1: 0.5 [42]. The Al-
lergan LD50 assay used ONA-BoNT/A and INCO-BoNT/A 
diluted in normal saline [72] to compare their activity. The ob-
tained results showed that one INCO-BoNT/A vial contained 
less than 100 Allergan units (i.e. 69-78 units for three different 
lots) and clearly suggested the non-interchangeability of units 
in the studied products. Additionally, these results were con-
firmed in an enzymatic cleavage assay, the Digit Abduction 
Score assay, as well as replication of the LD50 results [78, 79]. 
Dressler et al. [73] indicated that assay conditions markedly in-
fluence potency measurements. Moreover, dose-response data 
of BoNT/A formulations is used to determine the therapeutic 
dose range as the ‘benefit–risk’ rate from acceptable efficacy 
and safety profiles. Significantly different muscle weakening 
efficacies identified as 50% maximal (median effective dose 
-ED50) have been reported for the three main BoNT/A prod-
ucts, and furthermore not equipotent units of the botulinum 
toxin formulations that are under experimental conditions 
were presented [36, 79]. 
Additionally, different quantities of 150 kDa (ng pro-
tein/100 U) of BoNT/A in formulation (the lowest in INCO-
BoNT/A and the highest in ONA-BoNT/A) were shown by 
Ferrari et al. [80] and Field et al. [81] (see also Table 1). Cal-
culated analysis shows differences between BoNT/A formula-
tions. The highest amount of neurotoxin per product unit (in 
pg) and the total amount of active BoNT-A (in ng) injected 
at the recommended dose for an adult lower limb and an 
adult upper limb were obtained for ABO-BoNT/A. However, 
the relative quantity of rBoNT/A assessed as a ratio quantity 
obtained by the EndoPep method to protein quantity tested 
by ELISA method demonstrated not significant differences 
in LC activity-tested BoNT/A formulations. This indicates 
that the 150 kDa neurotoxin molecules in each product are 
equally active [81].  
Some studies have shown the non-interchangeability of 
units of ONA-BoNT/A and INCO-BoNT/A.   The highest total 
amount of active BoNT/A being found after injection of ABO-
BoNT/A to lower and upper limbs may suggest a focus on the 
conversion rate between ONA-BoNT/A and ABO-BoNT/A or 
INCO-BoNT/A and ABO-BoNT/A.
Summary
The major difference in structure between BoNT/A for-
mulations concerns the presence or absence of complexing 
proteins. The effectiveness of BoNT/A preparations is not de-
pendent on complexing proteins, but they may increase the risk 
of the formation of neutralising antibodies. The mechanism of 
action of all BoNT/A is similar, but the central effects of ONA-
BoNT/A may expand indications for its use in major depres-
sion. Diffusion and spread out for all formulations of BoNT/A 
is similar in most studies. The retrograde axonal transport and 
transcytosis to second-order nociceptive neurons described for 
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ONA-BoNT/A only justifies its usefulness in the treatment of 
chronic migraine. The non-interchangeability of units of ONA-
BoNT/A and INCO-BoNT/A was shown in an animal study, 
and the highest total amount of active BoNT/A after ABO-
BoNT/A injection to lower and upper limbs may suggest the 
need for additional studies  in other indications to confirm the 
correct conversion rate doses between BoNT/A preparations. 
Based on the differences in biological assays and the 
variations of biological activity [82, 83], regulatory agencies 
in most countries worldwide require a statement of unit non-
interchangeability among BoNT/A products.
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